BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld Asia
Home
» Biocompatibles in $422M Deal With AstraZeneca in Diabetes
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Biocompatibles in $422M Deal With AstraZeneca in Diabetes
Dec. 24, 2008
By
Nuala Moran
No Comments
LONDON - Biocompatibles International plc sealed a deal with AstraZeneca plc worth a potential €302.3 million (US$422.6 million) for a glucagon-like peptide (GLP-1) analogue for treating diabetes and obesity. (BioWorld International)
BioWorld Asia